Glycemic Management

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.

The FDA approved the SGLT2 inhibitor dapagliflozin to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release.

A continuous glucose monitoring system has the capability to connect directly with the Apple Watch for people with diabetes, according to a press release from Dexcom.

A once-weekly basal insulin conferred noninferior reductions in HbA1c among insulin-naive adults with type 2 diabetes and those who receive multiple daily insulin injections, according to top-line results from two phase 3 trials.

Pregnant women with type 1 diabetes achieved a higher time in range and had fewer complications with use of a hybrid closed-loop insulin delivery system compared with continuous glucose monitoring alone, according to a speaker.

A once-weekly basal insulin conferred similar changes in HbA1c and time in range as once-daily insulin glargine among adults with type 1 and type 2 diabetes in three phase 2 trials, according to a speaker.

The FDA granted 510(k) clearance for an automated insulin delivery system that can measure the volume and flow of insulin within every micro-dose, according to an industry press release.

The FDA cleared for marketing an over-the-counter continuous glucose monitor for adults with or without diabetes, according to an agency press release.

Adults with type 1 diabetes who have greater insulin sensitivity as measured by estimated glucose disposal rate are more likely to have better glycemic control, according to study data.

The FDA granted fast track designation for an immunotherapy to treat type 1 diabetes among people with the human leukocyte antigen DR3-DQ2 genotype, according to a press release.